March 20, 2017
Mar 20, 2017
PROVIDENCE, RI & PLYMOUTH, MN (March 20, 2017) – XIMEDICA, the leading medical technologies development firm today announced that it will relocate its Minneapolis office to a new space in Plymouth, MN. The move will accommodate continued local staff growth and provide a stronger presence in the Midwest with a more flexible and accessible venue for meetings, product demonstrations and events, capitalizing on a vibrant medical device community. The move is effective March 20, 2017.
“The relocation comes as a result of the company’s extraordinary growth over the past few years, with our most recent acquisition of Accel Biotech, based in Los Gatos, CA, and our past acquisition of Bridge Design in San Francisco. We’re proud to say Ximedica’s workforce has increased to employing 270 people across the U.S. and in Hong Kong,” says Randall S. Barko, Ximedica’s President and Chief Executive Officer.
The new 19,000 square feet of office space will be located at 2840 Vicksburg Lane in Plymouth, MN. Ximedica will host a ribbon-cutting ceremony and welcome reception in Plymouth with clients, community leaders, and employees on May 10th, 2017.
Adds Barko, “This new development space will enable the Midwest regional office to continue to expand its significant presence in Minnesota, as well as accommodate our regional clients more effectively and efficiently. We’re excited to open our doors in Plymouth.”
Ximedica is a full-service ISO 13485-certified and FDA-registered product development firm. For 30 years Ximedica has provided a unique growth platform enabling organizations to successfully deploy medical technology products into the market. Its headquarters are in Providence, R.I., with offices in Hong Kong, Minneapolis, San Francisco and Los Gatos. In November of 2014, SV Life Sciences, a Boston-based private equity firm, acquired a majority stake in Ximedica, enabling the company to execute its growth strategy. www.ximedica.com